Date:
January 25, 2021
Issue #:
1616
Summary:
The FDA has approved Semglee (Mylan), an insulin
glargine product similar to Lantus, for treatment of
type 1 diabetes in children and adults and type 2
diabetes in adults. Semglee is the second “follow-on”
insulin glargine product to become available in
the US; Basaglar, which is also similar to Lantus, was
the first. Lantus is a recombinant analog of human
insulin that forms microprecipitates in subcutaneous
tissue, prolonging its duration of action to a mean of
about 24 hours with no pronounced peak effect.
glargine product similar to Lantus, for treatment of
type 1 diabetes in children and adults and type 2
diabetes in adults. Semglee is the second “follow-on”
insulin glargine product to become available in
the US; Basaglar, which is also similar to Lantus, was
the first. Lantus is a recombinant analog of human
insulin that forms microprecipitates in subcutaneous
tissue, prolonging its duration of action to a mean of
about 24 hours with no pronounced peak effect.
